The global neurology clinical trials market size is expected to reach USD 8,052.9 million by 2030, registering a CAGR of 5.6% from 2023 to 2030. This is largely attributed to big pharma companies conducting innovative trials in neurology, increased government funding from the National Institute of Neurological Disorders and Stroke (NINDS), and the high prevalence of neurological disorders worldwide.
Neuroscience continues to receive a healthy investment. For instance, in November 2022, NRG Therapeutics raised Series A funding of USD 18.3 million for the development of mitochondrial therapeutics to treat neurodegenerative ailments such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. The adoption of similar initiatives in the future is expected to support market growth.
A significant number of people worldwide suffer from neurological disorders. For instance, as per the statistics from Parkinson's Foundation, every year 60,000 Americans are diagnosed with PD and more than 10 million people are living with the disease around the world. In terms of Epilepsy, the WHO states that more than 65 million people worldwide are affected by it. The disease is most prevalent in low- and middle-income countries, which account for 80.0% of epilepsy cases. A high prevalence of neurological disorders is expected to boost demand for clinical trials and thus support the market.
Neurology is considered as one of the major areas where clinical trials are conducted. As per the Pharma R&D Annual Review, in 2021, Neurology trials were the third area where clinical trials were majorly focused. The Pharma R&D Annual Review stated that for neurology above 2,900 drugs were under trial and in the year 2022 the number of drugs for clinical studies in the area of neurology accounted for more than 3,200 active drugs. An increasing number of drugs entering clinical trials in the area of neurology are expected to support the market in the post-pandemic period.
Neuroscience continues to receive a healthy investment. For instance, in November 2022, NRG Therapeutics raised Series A funding of USD 18.3 million for the development of mitochondrial therapeutics to treat neurodegenerative ailments such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. The adoption of similar initiatives in the future is expected to support market growth.
A significant number of people worldwide suffer from neurological disorders. For instance, as per the statistics from Parkinson's Foundation, every year 60,000 Americans are diagnosed with PD and more than 10 million people are living with the disease around the world. In terms of Epilepsy, the WHO states that more than 65 million people worldwide are affected by it. The disease is most prevalent in low- and middle-income countries, which account for 80.0% of epilepsy cases. A high prevalence of neurological disorders is expected to boost demand for clinical trials and thus support the market.
Neurology is considered as one of the major areas where clinical trials are conducted. As per the Pharma R&D Annual Review, in 2021, Neurology trials were the third area where clinical trials were majorly focused. The Pharma R&D Annual Review stated that for neurology above 2,900 drugs were under trial and in the year 2022 the number of drugs for clinical studies in the area of neurology accounted for more than 3,200 active drugs. An increasing number of drugs entering clinical trials in the area of neurology are expected to support the market in the post-pandemic period.
Neurology Clinical Trials Market Report Highlights
- The phase II segment dominated the market and accounted for a maximum revenue share of 46.3% in 2022. A majority number of neurology clinical trials are currently in Phase 2, this is supporting the segment market
- The interventional segment held the largest market revenue share of 96.1% in 2022. A high number of neurology clinical trials conducted through this study design type is promoting the growth of the segment market
- The Huntington's disease segment is anticipated to register the fastest CAGR of 6.0% during the forecast period. This is largely due to the fact that there is a high demand for the medicines used for Huntington's disease worldwide as there are no medications available for treating this disease
- North America dominated the market and accounted for a revenue share of 47.0% in 2022. The rising prevalence of neurological disorders and the presence of a large number of players in clinical trials drive the market in the region. These are some of the key reasons for the high market share
Table of Contents
Chapter 1. Methodology and Scope1.1. Market Segmentation & Scope
1.1.1. Phase
1.1.2. Study Design
1.1.3. Indication
1.1.4. Indication by Study Design
1.1.5. Indication by Phase
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. Neurology Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & growth prospect mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Increasing prevalence of neurological diseases such as Alzheimer disease, epilepsy, and stroke
3.3.1.2. Growing adoption of novel technologies in clinical research
3.3.1.3. Significant number of CROs providing neurology clinical research services
3.3.1.4. Increasing funding for neurological studies by public organizations
3.3.2. Market restraint analysis
3.3.2.1. High cost associated with neurology clinical studies.
3.3.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials.
3.4. Neurology Clinical Trials Market Analysis Tools
3.4.1. Porter’s Five Forces Analysis
3.4.2. PEST Analysis
3.5. COVID-19 Impact and Reformation Strategy
Chapter 4. Neurology Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. Definitions and Scope
4.2. Neurology Clinical Trials Market: Phase Market Share Analysis, 2022 & 2030
4.2.1. Phase I
4.2.2. Phase II
4.2.3. Phase III
4.2.4. Phase IV
Chapter 5. Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. Definitions and Scope
5.2. Neurology Clinical Trials Market: Study Design Market Share Analysis, 2022 & 2030
5.2.1. Interventional
5.2.2. Observational
5.2.3. Expanded Access
Chapter 6. Neurology Clinical Trials Market: Indication Estimates & Trend Analysis
6.1. Definitions and Scope
6.2. Neurology Clinical Trials Market: Indication Market Share Analysis, 2022 & 2030
6.2.1. Epilepsy
6.2.2. Parkinson's Disease (PD)
6.2.3. Huntington's Disease
6.2.4. Stroke
6.2.5. Traumatic Brain Injury (TBI)
6.2.6. Amyotrophic Lateral Sclerosis (ALS)
6.2.7. Muscle regeneration
6.2.8. Others
Chapter 7. Neurology Clinical Trials Market: Indication By Study Design Estimates & Trend Analysis
7.1. Definitions and Scope
7.2. Neurology Clinical Trials Market: Indication By Study Design Market Share Analysis, 2022 & 2030
7.2.1. Epilepsy
7.2.1.1. Interventional
7.2.1.2. Observational
7.2.1.3. Expanded Access
7.2.2. Parkinson's Disease (PD)
7.2.2.1. Interventional
7.2.2.2. Observational
7.2.2.3. Expanded Access
7.2.3. Huntington's Disease
7.2.3.1. Interventional
7.2.3.2. Observational
7.2.3.3. Expanded Access
7.2.4. Stroke
7.2.4.1. Interventional
7.2.4.2. Observational
7.2.4.3. Expanded Access
7.2.5. Traumatic Brain Injury (TBI)
7.2.5.1. Interventional
7.2.5.2. Observational
7.2.5.3. Expanded Access
7.2.6. Amyotrophic Lateral Sclerosis (ALS)
7.2.6.1. Interventional
7.2.6.2. Observational
7.2.6.3. Expanded Access
7.2.7. Muscle regeneration
7.2.7.1. Interventional
7.2.7.2. Observational
7.2.7.3. Expanded Access
7.2.8. Others
7.2.8.1. Interventional
7.2.8.2. Observational
7.2.8.3. Expanded Access
Chapter 8. Neurology Clinical Trials Market: Indication By Phase Estimates & Trend Analysis
8.1. Definitions and Scope
8.2. Neurology Clinical Trials Market: Indication By Phase Market Share Analysis, 2022 & 2030
8.2.1. Epilepsy
8.2.1.1. Phase I
8.2.1.2. Phase II
8.2.1.3. Phase III
8.2.1.4. Phase IV
8.2.2. Parkinson's Disease (PD)
8.2.2.1. Phase I
8.2.2.2. Phase II
8.2.2.3. Phase III
8.2.2.4. Phase IV
8.2.3. Huntington's Disease
8.2.3.1. Phase I
8.2.3.2. Phase II
8.2.3.3. Phase III
8.2.3.4. Phase IV
8.2.4. Stroke
8.2.4.1. Phase I
8.2.4.2. Phase II
8.2.4.3. Phase III
8.2.4.4. Phase IV
8.2.5. Traumatic Brain Injury (TBI)
8.2.5.1. Phase I
8.2.5.2. Phase II
8.2.5.3. Phase III
8.2.5.4. Phase IV
8.2.6. Amyotrophic Lateral Sclerosis (ALS)
8.2.6.1. Phase I
8.2.6.2. Phase II
8.2.6.3. Phase III
8.2.6.4. Phase IV
8.2.7. Muscle regeneration
8.2.7.1. Phase I
8.2.7.2. Phase II
8.2.7.3. Phase III
8.2.7.4. Phase IV
8.2.8. Others
8.2.8.1. Phase I
8.2.8.2. Phase II
8.2.8.3. Phase III
8.2.8.4. Phase IV
Chapter 9. Neurology Clinical Trials Market: Regional Estimates & Trend Analysis
9.1. Regional market share analysis, 2022 & 2030
9.2. North America
9.2.1. U.S.
9.2.1.1. U.S. market estimates and forecast, 2018-2030
9.2.2. Canada
9.2.2.1. Canada market estimates and forecast, 2018-2030
9.3. Europe
9.3.1. U.K.
9.3.1.1. U.K. market estimates and forecast, 2018-2030
9.3.2. Germany
9.3.2.1. Germany market estimates and forecast, 2018-2030
9.3.3. France
9.3.3.1. France market estimates and forecast, 2018-2030
9.3.4. Italy
9.3.4.1. Italy market estimates and forecast, 2018-2030
9.3.5. Spain
9.3.5.1. Spain market estimates and forecast, 2018-2030
9.4. Asia Pacific
9.4.1. Japan
9.4.1.1. Japan market estimates and forecast, 2018-2030
9.4.2. China
9.4.2.1. China market estimates and forecast, 2018-2030
9.4.3. India
9.4.3.1. India market estimates and forecast, 2018-2030
9.4.4. Australia
9.4.4.1. Australia market estimates and forecast, 2018-2030
9.4.5. South Korea
9.4.5.1. South Korea market estimates and forecast, 2018-2030
9.5. Latin America
9.5.1. Brazil
9.5.1.1. Brazil market estimates and forecast, 2018-2030
9.5.2. Mexico
9.5.2.1. Mexico market estimates and forecast, 2018-2030
9.5.3. Argentina
9.5.3.1. Argentina market estimates and forecast, 2018-2030
9.5.4. Colombia
9.5.4.1. Colombia market estimates and forecast, 2018-2030
9.6. MEA
9.6.1. South Africa
9.6.1.1. South Africa market estimates and forecast, 2018-2030
9.6.2. Saudi Arabia
9.6.2.1. Saudi Arabia market estimates and forecast, 2018-2030
9.6.3. UAE
9.6.3.1. UAE market estimates and forecast, 2018-2030
Chapter 10. Competitive Landscape
10.1. Market Share Analysis
10.2. Participant Categorization
10.3. Recent Development and Impact Analysis
Chapter 11. Company Profiles
11.1. Company Overview
11.2. Financial Performance
11.3. Strategic Initiatives
11.3.1. Expansions
11.3.2. Partnerships and Collaborations
11.3.3. Acquisitions
11.3.3.1. Novartis
11.3.3.2. Covance
11.3.3.3. Med pace
11.3.3.4. Charles River Laboratories
11.3.3.5. Syneous Health
11.3.3.6. Icon Plc
11.3.3.7. GlaxoSmithKline
11.3.3.8. Aurora healthcare
11.3.3.9. Biogen
11.3.3.10. IQVIA
List of Tables
Table 1 List of secondary sources
TABLE 2 List of Abbreviations
List of Figures
Fig. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market segmentation & scope
FIG. 8 Neurology Clinical Trials market outlook, 2018 - 2030
FIG. 9 Market trends & outlook
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 13 Porter’s Five Forces Analysis
FIG. 14 Neurology Clinical Trials market : Phase outlook key takeaways
FIG. 15 Neurology Clinical Trials market : Phase movement analysis
FIG. 16 Active Pharmaceutical Ingredients (API) market, 2018 - 2030 (USD Million)
FIG. 17 Phase I market, 2018 - 2030 (USD Million)
FIG. 18 Phase II market, 2018 - 2030 (USD Million)"Fig. 19 Phase III market, 2018 - 2030"Fig. 20 Phase IV market, 2018 - 2030 (USD Million)
FIG. 21 Neurology Clinical Trials market : Indication outlook key takeaways
FIG. 22 Neurology Clinical Trials market : Indication movement analysis
FIG. 23 Epilepsy market, 2018 - 2030
FIG. 24 Parkinson's Disease (PD) market, 2018 - 2030 (USD Million)
FIG. 25 Huntington's Disease market, 2018 - 2030 (USD Million)
FIG. 26 Stroke market, 2018 - 2030 (USD Million)
FIG. 27 Traumatic Brain Injury (TBI) market, 2018 - 2030 (USD Million)
FIG. 28 Stroke market, 2018 - 2030 (USD Million)
FIG. 29 Amyotrophic Lateral Sclerosis (ALS) market, 2018 - 2030 (USD Million)
FIG. 30 Muscle regeneration market, 2018 - 2030 (USD Million)
FIG. 31 Others market, 2018 - 2030 (USD Million)
FIG. 32 Neurology Clinical Trials market: Study Design outlook key takeaways
FIG. 33 Neurology Clinical Trials market: Study Design movement analysis
FIG. 34 Interventional market, 2018 - 2030 (USD Million)
FIG. 35 Observational market, 2018 - 2030 (USD Million)
FIG. 36 Expanded Access, 2018 - 2030 (USD Million)
FIG. 37 Neurology Clinical Trials market: Indication by Study Design outlook key takeaways
FIG. 38 Neurology Clinical Trials market: Indication by Study Design movement analysis
FIG. 39 Epilepsy interventional studies market, 2018 - 2030 (USD Million)
FIG. 40 Epilepsy observational studies market, 2018 - 2030 (USD Million)
FIG. 41 Epilepsy expanded acess studies market, 2018 - 2030 (USD Million)
FIG. 42 Parkinson's Disease (PD) interventional studies market, 2018 - 2030 (USD Million)
FIG. 43 Parkinson's Disease (PD) observational studies market, 2018 - 2030 (USD Million)
FIG. 44 Parkinson's Disease (PD) expanded acess studies market, 2018 - 2030 (USD Million)
FIG. 45 Huntington's Disease interventional studies market, 2018 - 2030 (USD Million)
FIG. 46 Huntington's Diseaseobservational studies market, 2018 - 2030 (USD Million)
FIG. 47 Huntington's Disease expanded acess studies market, 2018 - 2030 (USD Million)
FIG. 48 Stroke interventional studies market, 2018 - 2030 (USD Million)
FIG. 49 Stroke observational studies market, 2018 - 2030 (USD Million)
FIG. 50 Stroke expanded acess studies market, 2018 - 2030 (USD Million)
FIG. 51 Traumatic Brain Injury (TBI) interventional studies market, 2018 - 2030 (USD Million)
FIG. 52 Traumatic Brain Injury (TBI) observational studies market, 2018 - 2030 (USD Million)
FIG. 53 Traumatic Brain Injury (TBI) expanded acess studies market, 2018 - 2030 (USD Million)
FIG. 54 Amyotrophic Lateral Sclerosis (ALS) interventional studies market, 2018 - 2030 (USD Million)
FIG. 55 Amyotrophic Lateral Sclerosis (ALS) observational studies market, 2018 - 2030 (USD Million)
FIG. 56 Amyotrophic Lateral Sclerosis (ALS) expanded acess studies market, 2018 - 2030 (USD Million)
FIG. 57 Muscle regeneration interventional studies market, 2018 - 2030 (USD Million)
FIG. 58 Muscle regeneration observational studies market, 2018 - 2030 (USD Million)
FIG. 59 Muscle regeneration expanded acess studies market, 2018 - 2030 (USD Million)
FIG. 60 Others interventional studies market, 2018 - 2030 (USD Million)
FIG. 61 Others observational studies market, 2018 - 2030 (USD Million)
FIG. 62 Others expanded acess studies market, 2018 - 2030 (USD Million)
FIG. 63 Neurology Clinical Trials market: Indication by Phase outlook key takeaways
FIG. 64 Neurology Clinical Trials market: Indication by Phase movement analysis
FIG. 65 "Epilepsy Phase I market, 2018 - 2030 (USD Million)"Fig. 66 Epilepsy Phase II market, 2018 - 2030 (USD Million)
FIG. 67 Epilepsy Phase III market, 2018 - 2030 (USD Million)
FIG. 68 Epilepsy Phase IV market, 2018 - 2030 (USD Million)
FIG. 69 Parkinson's Disease (PD) Phase I market, 2018 - 2030 (USD Million)
FIG. 70 Parkinson's Disease (PD) Phase II market, 2018 - 2030 (USD Million)
FIG. 71 Parkinson's Disease (PD) Phase III market, 2018 - 2030 (USD Million)
FIG. 72 Parkinson's Disease (PD) Phase IV market, 2018 - 2030 (USD Million)
FIG. 73 Huntington's Disease Phase I market, 2018 - 2030 (USD Million)
FIG. 74 Huntington's Disease Phase II market, 2018 - 2030 (USD Million)
FIG. 75 Huntington's Disease Phase III market, 2018 - 2030 (USD Million)
FIG. 76 Huntington's Disease Phase IV market, 2018 - 2030 (USD Million)
FIG. 77 Stroke Phase I market, 2018 - 2030 (USD Million)
FIG. 78 Stroke Phase II market, 2018 - 2030 (USD Million)
FIG. 79 Stroke Phase III market, 2018 - 2030 (USD Million)
FIG. 80 Stroke Phase IV market, 2018 - 2030 (USD Million)
FIG. 81 Traumatic Brain Injury (TBI) Phase I market, 2018 - 2030 (USD Million)
FIG. 82 Traumatic Brain Injury (TBI) Phase II market, 2018 - 2030 (USD Million)
FIG. 83 Traumatic Brain Injury (TBI) Phase III market, 2018 - 2030 (USD Million)
FIG. 84 Traumatic Brain Injury (TBI) Phase IV market, 2018 - 2030 (USD Million)
FIG. 85 Amyotrophic Lateral Sclerosis (ALS)Phase I market, 2018 - 2030 (USD Million)
FIG. 86 Amyotrophic Lateral Sclerosis (ALS) Phase II market, 2018 - 2030 (USD Million)
FIG. 87 Amyotrophic Lateral Sclerosis (ALS) Phase III market, 2018 - 2030 (USD Million)
FIG. 88 Amyotrophic Lateral Sclerosis (ALS) Phase IV market, 2018 - 2030 (USD Million)
FIG. 89 Muscle regeneration Phase I market, 2018 - 2030 (USD Million)
FIG. 90 Muscle regeneration Phase II market, 2018 - 2030 (USD Million)
FIG. 91 Muscle regeneration Phase III market, 2018 - 2030 (USD Million)
FIG. 92 Muscle regeneration Phase IV market, 2018 - 2030 (USD Million)
FIG. 93 Others Phase I market, 2018 - 2030 (USD Million)
FIG. 94 Others Phase II market, 2018 - 2030 (USD Million)
FIG. 95 Others Phase III market, 2018 - 2030 (USD Million)
FIG. 96 Others Phase IV market, 2018 - 2030 (USD Million)
FIG. 97 Regional market place: Key takeaway
FIG. 98 Neurology Clinical Trials regional outlook, 2020 & 2028
FIG. 99 North America Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 100 U.S. Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 101 Canada Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 102 Europe Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 103 Germany Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 104 France Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 105 U.K. Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 106 Spain Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 107 Italy Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 108 Asia Pacific Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 109 Japan Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 110 India Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 111 China Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 112 South Korea Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 113 Australia Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 114 Latin America Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 115 Brazil Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 116 Mexico Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 117 Argentina Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 118 Colombia Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 119 Middle East & Africa Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 120 South Africa Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 121 Saudi Arabia Neurology Clinical Trials market, 2018 - 2030 (USD Million)
FIG. 122 UAE Neurology Clinical Trials market, 2018 - 2030 (USD Million)
Companies Mentioned
- Novartis
- Covance
- Med pace
- Charles River Laboratories
- Syneous Health
- Icon Plc
- GlaxoSmithKline
- Aurora healthcare
- Biogen
- IQVIA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 5235.8 Million |
| Forecasted Market Value ( USD | $ 8052.9 Million |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
